Bruker (BRKR) and Seer (SEER) each claimed favorable outcomes after the US Patent Trial and Appeal Board issued a ruling on US Patent No. 11,435,360, a proteomics-technology patent owned by Brigham and Women's Hospital and exclusively licensed to Seer.

Bruker said Tuesday the decision invalidated the patent's sole independent claim in a USPTO patent-challenge proceeding brought by its subsidiaries PreOmics and Biognosys.

Seer, citing the same ruling, said Monday the board upheld 23 claims of the patent, including five of the claims challenged by Bruker's subsidiaries, preserving broad protection for the nanoparticle-based protein-enrichment methods underlying its Proteograph platform. The company said the decision affirms the strength of its intellectual-property position.

The '360 patent covers methods using engineered nano- and microparticles to form protein coronas and detect proteins across a wide concentration range, enabling deep proteomic analysis.

Bruker shares rose 4% in Tuesday trading, and Seer gained 0.3%.

Price: 35.69, Change: +1.38, Percent Change: +4.02